Trending: Novartis Shares Climb on Guidance Lift
1240 GMT - Novartis is among the most mentioned companies across news items over the past 12 hours, according to Factiva data. The Swiss pharma giant's shares surged after it lifted its full-year guidance on profit and sales that rose in the first quarter. The stock traded 5.4% higher at CHF92.03 earlier, making it one of today's best performers in the Stoxx 600 index. Shares of Novartis grew 7.2% year-to-date. In addition to Novartis's first-quarter results beating expectations, the company also confirmed it isn't experiencing any drug shortages following its strategic refocus on specialty medicines in its four core therapeutic areas, which it undertook last year, Chief Financial Officer Harry Kirsch said in a press call. Dow Jones & Co. owns Factiva. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 23, 2024 08:55 ET (12:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now